Welcome to Markets Desk, your midday read on what's moving and why.
Oil is leading the macro story this hour, with crude jumping more than two percent after Iran's supreme leader declared that enriched uranium must remain inside the country. That hardline stance throws a significant wrench into ongoing U.S.-Iran peace talks, and traders are pricing in the risk of prolonged tension. Energy names are catching a bid as a result, and Wall Street futures are pointing to a softer open, with geopolitical uncertainty doing what it always does — suppressing risk appetite before the bell rings.
Shifting to pharma, Eli Lilly is generating serious attention after new trial data showed its experimental weight-loss injection produced twenty-eight percent body weight reduction in patients. That figure meaningfully outpaces what Zepbound and Mounjaro have delivered, and it signals Lilly isn't done pushing the frontier in the obesity space. Expect the stock and its competitors to trade actively on that headline through the session.
And in earnings, Ralph Lauren posted a profit increase in its fourth quarter, a result that speaks to the resilience of premium consumer spending even as broader retail has shown cracks. The brand continues to demonstrate pricing power, and that's a data point worth watching as we assess where the higher-end consumer actually stands heading into the second half of the year.
That's the tape. Markets Desk, signing off the floor.
